King Pharmaceuticals KG Legacy Reinsurance — Gross premiums written
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PremiumsWrittenGross.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's legacy reinsurance — gross premiums written.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is King Pharmaceuticals's legacy reinsurance — gross premiums written?
- King Pharmaceuticals (KG) reported legacy reinsurance — gross premiums written of $2.66M in Q1 2026.
- What does legacy reinsurance — gross premiums written mean?
- Represents the total premiums written by the legacy reinsurance segment before the deduction of reinsurance ceded. This metric measures the top-line volume of business underwritten by the segment and reflects its market reach and underwriting activity.